---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-047560"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2022-04-20T23:59:59+00:00"
generated_at: "2026-06-26T06:15:38.266775+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed

## Summary
- Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.
- Global COVID-19 testing sales $3.3B in Q1; full-year testing sales projected ~$4.5B, mostly in H1.
- Full-year 2022 adjusted EPS guidance reaffirmed at least $4.70; GAAP EPS at least $3.35.
- Nutrition sales -7% reported (-4.4% organic) due to infant formula recall; excluding recall, Nutrition +5%.
- Medical Devices +7.4% reported (+11.5% organic); FreeStyle Libre sales ~$1.0B (+20.4% reported).

## SEC filing metadata
- accession: 0001104659-22-047560
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2022-04-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/0001104659-22-047560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/tm2213006d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-047560
- JSON: https://secwatch.observer/filing/0001104659-22-047560.json
- Plain text: https://secwatch.observer/filing/0001104659-22-047560.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.